84449-90-1 Usage
Application in Particular Diseases
In Osteoporosis:
Raloxifene is an estrogen agonist on bone but an antagonist on the breast and uterus. It is approved for prevention and treatment of postmenopausal osteoporosis. Other estrogen agonists/antagonists may be approved soon (e.g., bazedoxifene, lasofoxifene).
Raloxifene decreases vertebral fractures and increases spine and hip BMD, but to a lesser extent than bisphosphonates. After discontinuation, the beneficial effect is lost and bone loss returns to age- or disease-related rates.
Raloxifene (like tamoxifen) is associated with decreased breast cancer risk. Raloxifene is associated with decreases in total and low-density lipoprotein cholesterol, neutral effects on high-density lipoprotein cholesterol, but slight increases in triglycerides; no beneficial cardiovascular effects have yet been demonstrated.
Raloxifene is well tolerated overall. Hot flushes occur more frequently in women recently finishing menopause or discontinuing estrogen therapy (ET). Endometrial bleeding occurs rarely. Raloxifene is contraindicated in women with an active or past history of venous thromboembolism. Therapy should be stopped if a patient anticipates extended immobility.
Chemical Properties
Light-Yellow Solid
Uses
Different sources of media describe the Uses of 84449-90-1 differently. You can refer to the following data:
1. A nonsteroidal estrogen receptor mixed agonist/antagonist
2. Raloxifene is a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Indications
Raloxifene (Evista) is a new SERM approved for
use in the treatment and prevention of osteoporosis because
it has estrogenic activity in bone. Raloxifene is an
estrogen antagonist in both breast and endometrial tissues.
The estrogenlike properties of raloxifene result in
the maintenance of a favorable serum lipid profile (decreased
low-density lipoprotein levels with no change
in either high-density lipoproteins or triglycerides).
Raloxifene is 95% bound to plasma proteins. Absorption
of raloxifene is impaired by cholestyramine.
Definition
ChEBI: A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
General Description
Raloxifene, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone (Evista), is a benzothiophene derivativethat differs slightly from the triphenylethyleneSERMs. A key structural difference is the carbonyl “hinge”that connects the modified phenolic side chain to the benzothiophenering system. This hinge is the key structural elementthat leads to the differing actions at the ERs.Raloxifene, unlike tamoxifen and toremifene, has antagonistproperties on the endometrium and breast tissue and agonistproperties on bone and the cardiovascular system. The lackof agonist action on endometrial tissue has been suggestedas a reason for the lack of endometrial cancer associatedwith raloxifene use. Raloxifene is approved for the preventionand treatment of osteoporosis in postmenopausalwomen. It has also been investigated for preventing breastcancer in comparison with tamoxifen. Recent studies indicatesthat it has similar effectiveness to tamoxifen, but has apreferable side effect profile.
Biological Activity
Selective estrogen receptor modulator (SERM) that binds to ER α and ER β , and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue, but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC 50 of 1 nM.
Clinical Use
Raloxifene, the first SERM
approved for the prevention of osteoporosis in postmenopausal women, acts as an estrogen agonist on
receptors in osteoblasts and osteoclasts but as an antagonist at breast and uterine estrogen receptors.
Check Digit Verification of cas no
The CAS Registry Mumber 84449-90-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,4,4,4 and 9 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 84449-90:
(7*8)+(6*4)+(5*4)+(4*4)+(3*9)+(2*9)+(1*0)=161
161 % 10 = 1
So 84449-90-1 is a valid CAS Registry Number.
InChI:InChI=1/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
84449-90-1Relevant articles and documents
Efficient synthesis of 3-benzoyl Benzo[b]thiophenes and raloxifene via Mercury(II)-Catalyzed cyclization of 2-alkynylphenyl alkyl sulfoxides
Wen, Shi-Ming,Lin, Cheng-Han,Chen, Chin-Chau,Wu, Ming-Jung
, p. 2493 - 2499 (2018/04/16)
The unique selective estrogen receptor modulator, Raloxifene (1), and antitubulin agent 2 were synthesized through the key intermediate, 4-methoxybenzyl 2-bromo-4-methoxyphenyl sulfoxide (6), respectively. It was found that compared with the o-sulfanyl aryl bromides, the sulfinyl group at ortho position accelerated the Sonogashira coupling reaction of aryl bromides. Thus, compound 6 was coupled with 3,4,5-trimethoxyphenyl acetylene, followed by mercury-catalyzed cyclization reaction afford compound 2 in 79% overall yield. Raloxifene (1) was prepared from compound 6 in four steps and 33% overall yield via coupling reaction with 1-trimethylsily-2-(4-tert-butyldimethylsiloxy)phenylethyne, mercury-catalyzed cyclization reaction, alkylation and demethylation.
Sulfoxide compound and method of producing benzothiophene derivatives using the same
-
, (2017/09/26)
A sulfoxide compound and method of producing benzothiophene derivatives using the same are provided. The sulfoxide compound is represented by formula (I), wherein R1 and R2 are individually and independently benzoyl group; alkyl, acyl or silyl group of C1-C6 straight chain or branched chain; or alkenyl group of C3-C6 straight chain or branched chain; and X is halogen atom. The sulfoxide compound reacts with alkynyl compound, and then the synthesis efficiency of benzothiophene derivatives can be effectively increased.
OXALIC ACID ADDITION SALTS AND/OR SOLVATES OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR
-
Page/Page column 28, (2014/09/29)
The present invention provides raloxifene oxalate, including derivatives thereof. In particular, the present invention provides solvates and/or hydrates of raloxifene oxalate, and polymorphs thereof. The present invention also provides processes for preparing the novel compounds, pharmaceutical compositions including the novel compounds and medical uses of the novel compounds.
